Proteome Sciences is a global leader in applied proteomics for human, veterinary and plant diseases. The technologies are used to identify biomarkers with diagnostic, prognostic and therapeutic applications and for monitoring disease progression/treatment across a range of important diseases that include stroke, TSEs, organ transplant rejection, diabetes/obesity and cancer.

PS Biomarker Services identifies biomarkers for predictive toxicology, drug responder profiling and for determining on- and off- pathway drug interactions during development of new therapeutic agents.

We continue to apply our PS Biomarker Services toolkit to further discover and validate new biomarkers and targets of disease. We are looking for partners to develop our existing biomarker portfolio for diagnostic and prognostic assays and as novel therapeutic targets.

As a research company, revenue is derived through out-licensing intellectual property from our disease biomarkers, through commercial collaborations and selective licensing of a number of the non-core Sensitizer® family and QC reagents.

Opportunities exist across all therapeutic areas to license Proteome Sciences’ proprietary biomarkers, enter into strategic alliances and outsourcing through PS Biomarker Services and for the selective licensing of Sensitizer® and QC reagents.

Details can be found under Products and Technologies.